Rapid Point of Care Testing for Infectious Disease

Rapid turnaround of test results is vital to decision-making for highly contagious infectious diseases. 

LamdaGen’s L’AuRa Digital Diagnostic platform enables real-time, lab-quality diagnostic results within minutes rather than hours or days.

LamdaGen Corporation is developing next generation rapid point of care testing (POCT) systems. The Company’s core technology is the L’AuRa digital platform that combines the high sensitivity and quantitation of lab-based testing (i.e. ELISA) with the simplicity and speed of lateral flow strip tests.

Our mission is to enable rapid, precise and cost-effective diagnostics for infectious disease and certain bio-pathogens at the point of need. By providing rapid turn-around times for key test results – first responders, medical staff and/or physicians can make better time-critical decisions.

LamdaGen’s patented L’AuRaDiagnostic technology is a digital platform that provides ELISA level quantitation and high sensitivity detection in a 15 minute format that significantly outperforms current rapid systems, including lateral flow tests.

L’AuRa is designed to be a simple, compact and cost effective CLIA-waivable system. Its powerful digital technology is easily integrated into designs ranging from miniaturized handhelds to small portable desktop systems.

We invite you to explore partnering opportunities with us.

For information, please email:  4info@lamdagen.com

LamdaGen is developing a high sensitivity rapid immuno-based antigen test for COVID-19. Click image to learn more.

LamdGen’s Micro-8 nano-based LSPR biosensors for multiplexed rapid and precise diagnostics

LamdGen’s Micro-8 nano-based biosensors for multiplexed targets


L’AuRa Digital Diagnostics

The L’AuRa diagnostic system is ideal for enabling high sensitivity, quantitative POC, mobile rapid testing.

Learn More ›

LSPR Biosensors

LamdaGen’s metallic thin-film LSPR-based Optical Biosensors for research and development in the areas of Life Science and Cleantech.

Learn More ›

News & Literature

Dual Acute COVID-19 Antigen and Flu A/B Point of Care Test in Development Read More ...

LamdaGen and COVID-19 Read More ...

LamdaGen and Arisan Receive $2 M NIH SBIR Phase II Grant to Advance Development of a Single, Rapid POC Assay for Detection of Acute Dengue and Zika Viral Infections Read More ...

More News >